Information Provided By:
Fly News Breaks for April 19, 2018
TKPYY, SHPG
Apr 19, 2018 | 11:44 EDT
B. Riley FBR analyst David Buck raised his price target for Shire (SHPG) to $200 after the company rejected an approach from Takeda Pharmaceutical (TKPYY) and Allergan confirmed interest in a potential acquisition. The analyst keeps a Buy rating on the shares.
News For SHPG;TKPYY From the Last 2 Days
There are no results for your query SHPG;TKPYY